Compare ORIO & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ORIO | EVAX |
|---|---|---|
| Founded | N/A | 2008 |
| Country | Canada | Denmark |
| Employees | 178 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 31.9M |
| IPO Year | N/A | 2020 |
| Metric | ORIO | EVAX |
|---|---|---|
| Price | $0.96 | $3.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 47.2K | 32.4K |
| Earning Date | 05-07-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $78.15 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.93 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $1.20 |
| 52 Week High | $1.40 | $12.15 |
| Indicator | ORIO | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 35.39 | 55.22 |
| Support Level | N/A | $2.45 |
| Resistance Level | $1.27 | $4.64 |
| Average True Range (ATR) | 0.06 | 0.36 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 18.92 | 44.32 |
Orion Digital Corp is a digital finance company operating across wealth, payments, and digital assets. Through its Investing wealth platform, Carta World-wide payments infrastructure, and long-duration Bitcoin treasury plan - combined with a disciplined, multi-engine compounding model. Orion Digital is focused on compounding value through execution, scale, and capital discipline.
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.